Research has shown significant gaps in knowledge on palliative services among neurology residents, resulting in low referral rates.
Investigators examined blood plasma samples taken annually from a cohort of 201 huntingtin gene (HTT) carriers.
Early onset of motor symptoms related to substance abuse appeared to significantly affect women compared with men.
Deutetrabenazine is only the second drug approved for patients with Huntington's disease.
The study supports the need for clinicians to initiate genetic counseling in patients who show clinical signs of HD.
The drug has a similar mechanism of action as tetrabenazine, but a different pharmacokinetic profile.
The HD-associated CAG repeat with 36 or more repeats was found in 18 individuals.
A new drug that inhibits the production of HTT mRNA may help slow progression of Huntington's disease.
The FDA has granted Orphan Drug designation to IONIS-HTT (Ionis) for the treatment of Huntington's disease.
Addressing proteasome dysfunction may help prevent accumulation of the toxic protein.
The FDA has accepted an application for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington's disease.
With no control group, researchers also considered that the positive response was a placebo effect.
Patients with bvFTD are more likely to exhibit criminal behavior like theft and public urination.
Neurology Advisor Articles
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Distinct Clinical Characteristics of Headache Associated With Subarachnoid Hemorrhage
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- Obesity and Alzheimer Disease: Exploring Risk Modification
- Increased Amyloid Burden With Obstructive Sleep Apnea
- Vigabatrin Beneficial for Focal Seizures in Tuberous Sclerosis Complex
- Number of Americans With Alzheimer Disease Expected to More Than Double by 2060
- Deep Brain Stimulation Improves Survival in Parkinson Disease